Sutro Biopharma, Inc. (STRO) NASDAQ
27.18
+2.75(+11.26%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
27.18
+2.75(+11.26%)
Currency In USD
| Previous Close | 24.43 |
| Open | 24.52 |
| Day High | 27.2 |
| Day Low | 23.63 |
| 52-Week High | 43.85 |
| 52-Week Low | 6.7 |
| Volume | 435,314 |
| Average Volume | 263,958 |
| Market Cap | 263.03M |
| PE | -1.66 |
| EPS | -16.35 |
| Moving Average 50 Days | 31.03 |
| Moving Average 200 Days | 16.92 |
| Change | 2.75 |
Sutro Biopharma Announces Participation at the 16th World ADC London Summit
GlobeNewswire Inc.
Feb 23, 2026 1:30 PM GMT
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced
Sutro Biopharma Announces Pricing of $110.0 million Underwritten Offering
GlobeNewswire Inc.
Feb 10, 2026 12:00 PM GMT
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (Nasdaq: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced
Sutro Biopharma to Present at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 07, 2026 9:05 PM GMT
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced